LeadArtis awarded with a RIS3 grant from the Comunidad Autónoma de Madrid in recognition of its highly innovative R&D activity.

08-03-2016

The Ministry of Economy and Finance of the Community of Madrid (MEFCAM), following the recommendations of the European Union, has established the regional strategy for research and innovation for smart specialization of the Community of Madrid framework (hereinafter RIS3) to support the development of highly specialized innovating companies with a requirement of permanent competitiveness. Consequently, the RIS3 grants are meant to increase innovative activity within the industry promoting innovative projects. As a result of an extremely competitive assessment of hundreds of business projects and companies, LeadArtis has been awarded with a substantial endowment that will be used to advancing its immune-oncology therapeutics pipeline.

LeadArtis is a preclinical stage health biotechnology company located in Madrid (www.leadartis.com) focused on producing multivalent immune stimulating antibodies through its unique Trimerbody® technology. The Trimerbodies exhibit excellent antigen binding capacity, functionality and stability.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)
31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy
15-01-2018

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...